Bardoxolone methyl
- Generic Name
- Bardoxolone methyl
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H43NO4
- CAS Number
- 218600-53-4
- Unique Ingredient Identifier
- CEG1Q6OGU1
- Indication
Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Registration Number
- NCT01551446
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT01549769
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 6
- Registration Number
- NCT01503866
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT01461161
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 33
- Registration Number
- NCT00529113
- Locations
- 🇺🇸
Central Indiana Cancer Centers (US Oncology), Indianapolis, Indiana, United States
🇺🇸Rocky Mountain Cancer Center (US Oncology), Denver, Colorado, United States
🇺🇸Cancer Centers of Florida (US Oncology), Ocoee, Florida, United States
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT00529438
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.